DISCUSSION DIFFERENTIAL DIAGNOSIS
Childhood epistaxis is a common complaint that usually abates in adulthood; however, epistaxis can be life threatening when episodes are frequent and accompanied by substantial blood loss (1 ) . A history of mucocutaneous hemorrhage, as opposed to hemarthrosis (bleeding into joint spaces) and muscle hemorrhage, helps to differentiate disorders of platelet function (including von Willebrand disease and afibrinogenemia) from the hemophilias and related disorders. Hemarthrosis is rarely seen in disorders of platelet function and occurs even more rarely in Glanzmann thrombasthenia (GT), whereas episodes of hemarthrosis can be frequent in hemophilia (1 ) .
Leukemia, idiopathic thrombocytopenic purpura, and allergic purpura should be included in the differential diagnosis of patients with mucocutaneous hemorrhage. When mucocutaneous hemorrhage is seen in leukemia, it is usually accompanied by thrombocytopenia in the peripheral blood. Patients with idiopathic thrombocytopenic purpura have decreased platelet counts and may have detectable antiplatelet antibodies. Allergic purpura (also called Henoch-Shönlein purpura) can be recognized by its clinical presentation, which typically includes joint inflammation, abdominal pain, and sometimes hematuria and renal damage.
DIAGNOSTIC TESTS FOR PLATELET FUNCTION DISORDERS
Abnormalities of platelet function have been associated with several acquired and inherited bleeding disorders. Common inherited causes of platelet-related bleeding include Bernard-Soulier syndrome, GT, and gray platelet syndrome. Table 2 summarizes common acquired disor-ders of platelet function, including those caused by aspirin consumption and those due to hematologic and systemic diseases. It is essential to assess platelet aggregation as part of the workup of individuals suspected of having an abnormal platelet function. Many of the conditions mentioned above exhibit characteristic abnormalities in platelet-aggregation studies. Aggregation testing for the child highlighted in this case was performed with light transmission aggregometry (LTA).
The International Society on Thrombosis and Hemostasis survey on LTA practices (2 ) has helped identify aspects of practice that lack standardization worldwide, including what agonists and agonist concentrations are used for testing. Guidelines to standardize and improve diagnostic testing for platelet function disorders have been published by the CLSI. When performed and interpreted in accordance with guidelines, LTA is useful in the evaluation of platelet function disorders. Laboratories should establish standard operating procedures to minimize preanalytical and analytical errors and develop appropriate reference intervals to guide the interpretation of results.
The first step in the evaluation of an unexpected platelet function disorder is to rule out preanalytical causes of imprecision (3 ). It is important to remember that many drugs (e.g., aspirin and dipyridamole) and some foods (e.g., garlic, black fungus, green tea, and red wine) affect platelet function. Patients should be advised to avoid taking platelet-inhibitory medications for up to 14 days before the test, and they should be asked about their current medications and diet before blood samples are obtained for the test. In addition, studies should not be conducted after the patient has consumed a fatty meal, because chylomicrons can interfere with LTA measurement of platelet aggregation.
For aggregation studies, platelets are separated from red blood cells and white blood cells, and plateletrich plasma (PRP) is prepared. PRP quality is influenced by both centrifugation conditions and the number of platelets in the PRP. Centrifugation of whole 
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blood at 200g to 250g for 10 min appears to be the best condition for preparing PRP for LTA studies (4 ) . A platelet count of the PRP is also required before performing aggregation studies. The number of platelets in the PRP will influence the aggregation responses. The best results are obtained when the platelet count for PRP is between 200 ϫ 10 9 /L and 600 ϫ 10 9 /L. Platelet aggregation is pH dependent; therefore, the PRP pH should be maintained between 7.4 and 7.8. PRP samples should be stored in full, tightly capped tubes, and testing should be completed within 4 h of preparation.
The choice of platelet-aggregating agents should be sufficient to allow discrimination between the various functional platelet disorders. The aggregating agents routinely used are ADP, epinephrine, ristocetin, collagen, and arachidonic acid. Table 1 lists the concentrations of agonists according to the CLSI guidelines (5 ). Bernard-Soulier syndrome lacks a platelet response only for ristocetin and is associated with thrombocytopenia and giant platelets. von Willebrand disease also has a reduced or absent ristocetin response, but platelet counts and morphology are normal. GT is characterized by a normal platelet-aggregation response to ristocetin only. Gray platelet syndrome lacks a platelet response to collagen or thrombin, but it shows a normal response to other aggregating agents. Ingestion of aspirin is characterized by absent or markedly reduced platelet aggregation in response to arachidonic acid only. Abnormalities in platelet aggregation in hematologic and systemic diseases are not specific; these abnormalities are usually recognized by their associated clinical features.
The second step in evaluating an abnormal platelet function result should be to repeat the aggregation assay and to ensure that potential preanalytical or analytical factors that might lead to false positives have been eliminated. If the pattern of aggregation and the clinical features suggest a genetic cause, confirmatory tests are appropriate (e.g., glycoprotein analysis to confirm GT or Bernard-Soulier syndrome) (6 ).
OVERVIEW OF GT
GT is a rare autosomal recessive disorder characterized by mucocutaneous bleeding and absent or severely reduced platelet aggregation in response to the physiological agonists ADP, epinephrine, and collagen, but relatively normal aggregation in response to ristocetin (7 ) .
Molecular genetic analysis of the ITGA2B 4 [integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)] gene, which encodes GPIIb, showed 2 heterozygous nonsense mutations (Gln517Stop and Arg553Stop). Gln517Stop is a novel mutation that has not previously been reported to the best of our knowledge. An analysis of family members indicated that the Gln517Stop and Arg553Stop mutations were located on different alleles and inherited from the patient's mother and father, respectively. Her parents were not consanguineous and had no bleeding symptoms. The results of laboratory tests for her parents were all normal, including the results of a flow cytometric analysis of GPIIb and GPIIIa. Nonsense mutations in humans have been found to reduce the accumulation of mutant mRNA (8 ) .
Molecular testing is considered appropriate for platelet disorders in pediatric patients with mucocuta- 4 Human genes: ITGA2B, integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41); ITGB3, integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61). neous bleeding and abnormal platelet aggregation. In addition, some patients with atypical laboratory results can be evaluated with molecular testing. Molecular testing can identify the pathogenic gene quickly and accurately. Thus, the disease can be diagnosed earlier, thereby allowing proper treatment. With the development of molecular diagnosis and widespread use of gene chips, prenatal diagnosis has become commonplace throughout the world (9 ) . The hemorrhagic diathesis in GT is notable for its variability and for the lack of a correlation between the biochemical platelet abnormalities and clinical severity (1). Thus, factors other than the platelet defect itself appear to play an important role in determining the risk of bleeding. 
